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LPS and  MTP-PE  (liposome-encapsulated  N-acetyl-
muramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-:[19 ,29 -
dipalmitoyl-sni-glycero-3-(hydroxy-phosphoryl-oxyl)]
etylamide)  induce  in  liver  macrophages a synthesis
and  release  of  TNF-a ,  nitric  oxide  and  prostanoids.
Both agents induce an expression of mRNA’s encod-
ing TNF-a , inducible nitric oxide synthase (iNOS) and
cyclooxygenase (COX)-2, and of corresponding pro-
teins. LPS and MTP-PE induce a rapid activation of the
extracellular  regulated  kinase  (ERK)  isoenzymes-1
and –2. Inhibition of map kinase isoenzymes leads to
a decreased release of TNF-a , nitric oxide and prosta-
glandin (PG) E2 after both agents. The transcription
factors NF-k B and AP-1 are strongly activated by LPS
within 30 minutes. MTP-PE induces a weak activation
of  both  transcription  factors  only  after  5  hours.
Inhibition of NF-k B inhibits the LPS- but not the MTP-
PE-induced release of TNF-a , nitric oxide and PGE2.
PGE2 release  after  LPS  is  higher  than  after  MTP-PE.
Exogenously  added  PGE2 inhibits  the  activation  of
map kinase and TNF-a release by LPS, but not by MTP-
PE.  Release  of  nitric  oxide  after  LPS  and  MTP-PE  is
enhanced  after  prior  addition  of  PGE2.  PGD2 is
without  any  effect.  MTP-PE,  but  not  LPS,  induces  a
cytotoxicity of Kupffer cells against P815 tumor target
cells. The MTP-PE-induced cytotoxicity is reduced by
TNF-a neutralizing antibodies, indicating the involve-
ment  of  TNF-a .  Thus  our  results  suggest  that  the
different potencies of LPS and MTP-PE as immunomo-
dulators  probably  result  from  different  actions  on
Kupffer cells, resulting in differences in the amounts
and  kinetics  of  released  TNF-a and  PGE2,  and  that
PGE2 plays an important regulatory role in the action
of LPS, but not in the actions of MTP-PE.
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Introduction
Liver  macrophages (Kupffer  cells)  are  macrophages
residing  in  the  sinusoids  of  the  liver. This  strategic
location makes them the first macrophages to come
into contact with noxious materials that enter circula-
tion via the portal vein. This location and the fact that
they constitute the largest pool of macrophages in the
body attributes to them an important function in the
clearance of noxious material, the removal of migrat-
ing tumor cells, and in the pathophysiology of septic
shock.1
Liver macrophages have been reported to secrete a
wide array of biologically active compounds including
cytokines,  prostanoids,  nitric  oxide  and  oxygen
radicals, which have been shown to be involved in
the pathogenesis of septic shock, and in the cytotox-
icity of Kupffer cells against tumor target cells.1–7
LPS and muramyl tripeptides are components of the
outer cell membrane of most bacteria and display most
of  the  immunological  activities  compared  with  an
infection of whole bacteria.8 –11 When administrated
i.v., LPS and liposome-encapsulated N-acetyl-muramyl-
L-alanyl-D-isoglutaminyl-L-alanine-2-[19 ,  29 dipalmitoyl-
sn-glycero-39 -(hydroxy-phosphoryl-oxyl)]  ethyl-amide
(MTP-PE)3 are  delivered  predominantly  to  macro-
phages, especially liver macrophages.12,13 While LPS
has  been  shown  to  play  a  significant  role  in  the
pathogenesis of gram-negative septic shock, muramyl
tripeptides have been demonstrated to be protective
against LPS-induced septicemia.14,15 Furthermore, i.v.
administered  MTP-PE  has  been  shown  to  induce
antitumor  reactivity,  probably  as  a  result  of  macro-
phage activation,16 –19 and to inhibit HIV replication in
macrophages.20
In contrast to LPS, very little is known about the
intracellular signal transduction pathways of muramyl
tripeptides. Recently, we showed that MTP-PE and LPS
induce similar reactions in liver macrophages, like the
formation  of TNF-a , nitric  oxide  and  prostanoids.21
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Mediators of Inflammation, 8, 295–303 (1999)Furthermore, we demonstrated, that cellular calcium
and protein kinase C isoenzymes are not involved in
the signal pathways of LPS and MTP-PE.21
Materials and methods
Materials
Medium RPMI 1640, newborn and fetal calf serum are
purchased  from  Biochrom  (Berlin,  Germany);  new-
born calf serum is heat-inactivated at 56°C for 30 min
[g -32ATP]  and  [3H]thymidine  are  from  Amersham
Buchler (Braunschweig, Germany). P815 mouse mas-
tocytoma and mouse L929 cells are purchased from
American Type  Culture  Collection  (Rockville,  USA).
Murine rTNF-a and rat TNF-a -neutralizing antibodies
are  from  Boehringer  Mannheim  (Mannheim,  Ger-
many)  and  IC  Chemikalien  (Ismaning,  Germany),
respectively.  BAY  11–7082  and  PD  98059  are  pur-
chased  from  Calbiochem  (Bad  Soden,  Germany).
Monoclonal antibodies against COX-2 and iNOS  are
purchased from Natutuec (Frankfurt, Germany) and
Transduction  Laboratories/Dianova  (Hamburg,  Ger-
many),  respectively.  MTP-PE  is  kindly  provided  by
Ciba-Geigy (Basel, Switzerland). LPS R595 from Sal-
monella minnesota is a gift  from Dr Galanos (Frei-
burg,  Germany).  Antibodies  raised  against  prosta-
glandin (PG) E2 and PGD2 are generous gifts from Dr
Brune (Erlangen, Germany) and Dr Hayaishi (Osaka,
Japan), respectively. RT -PCR reagents and enzymes are
from Perkin  Elmer  (Weiterstadt,  Germany). Specific
primers  (HPLC  purified)  are  synthesized  and  pur-
chased  from  Birsner  &  Grob  (Denzlingen,
Germany).
Cell culture
Livers  of  male  Wistar  rats  (Charles  River,  Sulzfeld,
Germany)  are  removed  aseptically  under  Nembutal
anaesthesia, and the liver macrophages are isolated by
a  centrifugal  elutriation  procedure.22 Liver  macro-
phages are maintained in primary culture with RPMI
1640 medium containing 30% newborn calf serum. All
experiments are performed with cells kept in primary
culture for 48–72h. P815  mouse mastocytoma cells
and  L929  cells  are  grown  in  RPMI  1640  medium
containing 10% FCS.
Determination of PGE2 and PGD2
Macrophages are incubated in RPMI medium contain-
ing 10% newborn calf serum with or without LPS or
MTP-PE, and after the indicated times cell media are
removed and centrifuged. The amount of PGE2 and
PGD2 in  cell media  is  measured by ELISA  and RIA,
respectively, as described elsewhere.23
Determination of TNF-a activity
The release of TNF-a activity is measured using the
L929 cell cytotoxicity assay in which lysis of actino-
mycin-D-treated L929  cells by TNF-a is measured by
crystal violet staining of survival cells in monolayer
culture.24 L929 cells are grown on 96-well microtest
plates  to  the  density  of  ~4´ 104 cells/well.  Culture
media to be tested are added to the wells together
with actinomycin (400 ng/well). After 24 h, the super-
natants  are  discharged  and  the  remaining  cells  are
stained  with  0.5%  crystal  violet  in  25%  aqueous
methanol for 10 min. The dye is removed by washing
three times with 25% methanol, and 5% SDS is added
to solubilize the adherent cells. Then the aborbance is
read  with  a  microplate  reader  (Titertek  Multiskan
Plus)  at  550 nm. The  absorbance  is  compared  with
that of a standard solution of murine rTNF-a . Units of
TNF-a activity are the reciprocal dilution factor of a
sample causing 50% lysis of L929 cells. The specificity
is controlled by neutralization with rat TNF-a -neutral-
izing antibodies (dilution of 1:50).
Determination of nitric oxide
Macrophages are incubated in RPMI medium contain-
ing 10% newborn calf serum with or without LPS or
MTP-PE, and after the indicated times cell media are
removed  and  centrifuged.  Nitric  oxide formation  is
measured  as  NO2
– accumulated  in  the  cell  media,
which  reflects  the  release  of  nitric  oxide  from
macrophages.3 The  Griess  reaction  using  20 m l  of
sulfanilamide  (10 mM),  10 m l  of HCl  (2M), 10 m l  of
naphtylethylenediamine dihydrochloride (1mM), and
150 m l  of  supernatant  is  applied  to  each  well  of  a
microtiter plate; the pink azo dye is quantitated by a
microplate reader (Titertek Multiskan Plus) at 550 nm.
Standards are prepared using NaNO2
–.
In vitro cytotoxicity assay
Macrophages  are  cultured  on  96-well  plates  at  a
density  of  ~105 cells/well.  P815  target  cells  in  the
exponential  growth  phase  are  radiolabeled  by  a
24 h-incubation  in  RPMI  medium  with  10%  FCS
containing 20 m Ci of [3H]thymidine/106 cells in 5 ml.
Then the cells are washed three times to remove the
radioisotope and resuspended in culture medium to a
concentration of 105 cells/ml. 100 m l (104 [3H]thymi-
dine-labeled target cells) is added to cultured macro-
phages in a total volume of 200 m l of medium/well.
LPS or MTP-PE is added to macrophages 6 h before the
addition of target cells. Radiolabeled target cells are
also plated alone as an additional control. 48 h after
the  addition  of  target  cells,  the  supernatants  are
collected and the radioactivity is measured in a liquid
scintillation counter. Cytolysis is calculated as follows:
%  cytolysis  =  100´ (a–b)/(c–b),  where  a=cpm  in
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phages,  b=cpm  in  supernatants  of  target  cells  cul-
tured alone, c=cpm in the total amount of target cells
added per well.
Western blot analysis
Total  protein  (10 m g)  is  separated  on  10%  poly-
acrylamide gels under reducing conditions. Proteins
are  transferred  to  nitrocellulose  membranes,  and
nonspecific binding is blocked by incubation in PBS
containing 0.1% Tween 20 and 5% milk powder. The
plots are probed with antibodies against COX-2 and
iNOS. After extensive washing, the blots are incubated
with  the  secondary  antibodies,  washed  extensively
and developed using the ECL Western blotting detec-
tion system (Amersham). For quantitative analysis, the
bands are scanned densitometrically.
In situ map-kinase assay
Map  kinase  activity  is  performed  by  an  in  vitro
renaturation assay.25,26 Cells are washed with PBS and
lysed  in  50 mM Tris-HCl, pH 7.5,  150 mM  NaCl,  1%
(w /v) Triton  X-100,  0.1 mM  Na3VO4,  1 mM  phenyl-
methylsulfonyl fluoride,  0.1 mM  aprotinin,  vortexed
and  centrifuged  at  15000´ g for  30 min. The  super-
natants  are  matched  for  protein  content  (BioRad
protein dye assay) and diluted to 1mg/ml protein in
62.5 mM Tris-HCl, pH 6.8, containing 2.3% (w /v) SDS,
5 mM EDTA, 10% (v/v) glycerol and 100 mM DTT and
heated at 86°C for 5 min before SDS–PAGE. The gels
are polymerized with 0.2mg/ml myelin basic protein
and, after electrophoresis, denatured in 6M guanidine
hydrochloride. After  renaturation,  the  gels  are  pre-
incubated in 25 mM HEPES, pH 7.4, 2mM 2-mercap-
toethanol, 10 mM MgCl2, 0.1 mM Na3VO4 and 0.5 mM
EGTA  at  30°C  for  30 min.  The  kinase  reaction  is
performed by incubation of the gels in 25 mM HEPES,
pH  7.4,  2 mM  2-mercaptoethanol,  10 mM  MgCl2,
0.1 mM  Na3VO4,  0.5 m M  EGTA,  25 m M  ATP  and
250 m Ci [g -32P]ATP.
Electrophoretic mobility shift assay
Determination of the DNA-binding capacity of NF-k B
and  AP-1  is  performed  exactly  as  described
previously.27
RT-PCR studies
RNA  from  macrophages  is  prepared  according  to
Chomzynski  and Sacchi.28 In  brief, 1–2´ 106 macro-
phages  are  frozen  in  liquid  nitrogen,  taken  up  in
guanidinium  thiocyanante  and  extracted  with  acid-
ified phenol/chloroform. After centrifugation, RNA is
precipitated from the aqueous phase with isopropa-
nol. The pellet is washed once with 80% ethanol and
then taken up in 10 m l H2O. The total amount of RNA
is  determined  spectrophotometrically  and  reverse
transcribed  (22°C/10 min–42°C/60 min–95°C/5 min/
4°C, Perkin Elmer PCR System 2400) using recombi-
nant  moloney  murine  leukemia  virus  reverse  tran-
scriptase  (2.5  units/m l)  in  500 mM  KCl,  100 mM
Tris–HCl,  pH  8.3,  5 m M  MgCl2,  2.5 m M  random
hexamers, 1 unit/m l RNAse inhibitor, 2.5 m M of each
dATP,  dCTP,  dGTP,  dTTP  and  approximately  0.5 mg
RNA  in a total volume of 10 m l. For PCR analysis, a
master  mix  is  prepared  containing  buffer  (500 mM
KCl, 100 mM Tris–HCl, pH 8.3), MgCl2 (final concen-
tration  1 mM)  and AmpliTaq  DNA  Polymerase  (final
concentration 1.25 units/50 m l). For single PCR analy-
sis,  35 m l  of  master  mix  solution,  5 m l  of  specific
primers and 10 m l of reverse-transcribed cellular RNA
are added. To compare the levels of mRNA  in  cells
treated  for  different  times  without  or  with  LPS  or
MTP-PE, b -actin is chosen to standardize the different
samples.  mRNA  levels  encoding  b -actin  did  not
change upon treatment of macrophages with LPS or
MTP-PE (data not shown). In previous experiments,
using different amounts of RNA and different amplifi-
cation  cycles,  the  amount  of  RNA  for  the  different
PCR reactions was then chosen so that the amount of
specific  amplified  products  increased  roughly  loga-
rithmically  between  25  and  35  cycles.  Final  PCR
conditions are as followed (Perkin Elmer PCR System
2400):
b -actin [1 ng cDNA, 0.5 m M primer
(CTCCTTAATGTCACGCACGATTTC/
GTGGGGCGCCCCAGGCACCA),
94°C/5min,  52°C  /5 min–72°C/2min–94°C/1 min
(30 cycles)–52°C/2min–72°C/10 min–4°C];
TNF-a [100 ng cDNA, 0.5 m M primer
(ATGAGCACAGAAAGCATGATC/
CAGAGCAATGACTCCAAAGTA),
94°C/5min,  52°C/5 min–72°C/2 min–94°C/1 min–
52°C/2 min (30 cycles)–72°C/10min–4°C];
COX-1 [10 ng cDNA, 0.5 m M primer
(TGCATGTGGCTGTGGAGTTCATCAA/
CACTAAGACAGACCCGTCTTCTCCA),
94°C/5min,  65°C  /5 min–72°C/2 min–94°C/1 min–
65°C/2 min (30 cycles)–72°C/10min–4°C];
COX-2 [100 ng cDNA, 0.5 m M primer
(ACTCACTCAGTTTGTTGAGTCATTC/
TTTGATTAGTACTGTAGGGTTAATG),
94°C/5min,  55°C/5 min–72°C/2 min–94°C/1 min–
55°C/2 min (30 cycles)–72°C/10min–4°C];
iNOS [100 ng cDNA, 500 ng primer
(GCTTGCCCCTGGAAGTTTCTC/
CCGACCTGATGTTGCCACTGT),
94°C/5min,  65°C/5 min–72°C/2 min–94°C/1 min–
65°C/2 min (30 cycles)–72°C/10 min–4°C]. 10 m l of
the PCR reaction are loaded onto a 1.5% agarose gel.
The  bands  (b -actin:  610bp, TNF-a :  710 bp,  COX-2:
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nator after ethidium bromide staining and, for semi-
quantitative  analysis,  scanned  densitometrically
(E.A.S.Y. RH, Herolab, Germany). To compare mRNA
expression  in  cells  treated  different  times  with  or
without LPS or MTP-PE, corresponding mRNA levels
are first calculated as expression compared to b -actin
mRNA, the resulting values of control cells are set to
1 and levels of mRNA in LPS- and MTP-PE-treated cells
are expressed as ‘fold of control cells’.
Results
Release of TNF-a , nitric oxide and
prostaglandins
LPS  and  MTP-PE  induce  a  synthesis  and  release  of
TNF-a , nitric oxide and prostanoids in macrophages
(Fig. 1). LPS induces a rapid and transient accumulation
P. Dieter et al.
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FIG. 1. Effect of LPS and MTP-PE on the release of TNF-a ,
nitric oxide, PGE2 and PGD2. Macrophages are incubated for
the indicated times in RPMI medium containing 10% new-
born calf serum with LPS (open symbols, 500ng/ml) or with
MTP-PE (closed symbols, 25 m g/ml). At indicated time points,
accumulation of TNF-a activity (A), nitric oxide (B), PGE2 (C,
circles), and PGD2 (C, triangles) in cell media is determined
as  described  in  Materials  and  Methods.  Values  represent
means ± SD of four experiments.
FIG. 2. RT-PCR analysis of mRNA isolated from unstimulated
macrophages. Macrophages are cultured for  72h  in RPMI
medium  containing  10%  newborn  calf  serum.  RNA  is
isolated and RT-PCR analysis is performed as described in
Materials and Methods. Marker, f X174/Hae III (1353, 1078,
872,  603,  310bp).  A  representative  set  of  experiments  is
shown which is reproduced at least six times.
FIG. 3. Effect  of LPS and MTP-PE on the accumulation of
mRNA encoding TNF-a , iNOS and COX-2. Macrophages are
incubated for the indicated times in RPMI medium contain-
ing 10% newborn calf serum with LPS (open circles, 500ng/
ml) or with MTP-PE (closed circles, 25 m g/ml). At indicated
time  points,  RNA  is  isolated  and  RT-PCR  analysis  is  per-
formed  as  described  in  Materials  and  Methods.  Values
represent means ± SD of four experiments.of TNF-a , MTP-PE-induced TNF-a release shows a lag
phase of about 6 h, and increases thereafter up to 48 h
(Fig. 1A). The release of nitric oxide (Fig. 1B) and PGD2
(Fig. 1C) is almost identical for both agents. The release
of PGE2 after LPS is higher than after MTP-PE (Fig. 1C).
mRNA and protein levels
In order to investigate at which levels LPS and MTP-PE
induce  the  formation  of  TNF-a ,  nitric  oxide  and
prostanoids, corresponding mRNA and protein levels
are determined by RT-PCR and Western blot analysis,
respectively. Figure 2 shows that unstimulated macro-
phages contain very small amounts of mRNAs encod-
ing TNF-a , iNOS and COX-2. mRNAs encoding b -actin
and COX-1 are expressed at much higher levels (Fig.
2). LPS induces a rapid and transient accumulation of
TNF-a mRNA  with  a maximum at  about 1.5 h (Fig.
3A). In contrast, TNF-a mRNA after MTP-PE becomes
detectable only after a lag phase of about 4 h. Both,
LPS and MTP-PE induce a rapid accumulation of iNOS
mRNA (Fig. 3B). The level of iNOS  mRNA after LPS
peaks  at  about  4 h,  and  declines  thereafter.  In
contrast, MTP-PE induces an increase of iNOS mRNA
up to 12 h, which remains thereafter elevated at this
level. COX-2 mRNA increases rapidly to similar levels
after the addition of LPS and MTP-PE (Fig. 3C). Resting
macrophages show no detectable amounts  of iNOS
and COX-2 protein (Fig. 4). Addition of LPS and MTP-
PE  induce  an  expression  of  both  proteins,  which
becomes detectable at first after 6–8 h. LPS induces a
higher  expression  of  iNOS  protein  (24 h),  COX-2
protein is higher expressed after MTP-PE.
Activation of ERK-1 and –2
Recently we demonstrated that calcium and protein
kinase C isoenzymes are not involved in the actions of
LPS  and  MTP-PE  in  macrophages.21 Here  we  show
(Fig. 5), that both agents induce a rapid activation of
the  map  kinase  isoenzymes  extracellular  regulated
kinase (ERK)-1 and ERK-2.
Activation of NF-k B and AP-1
LPS  induces  a  rapid  activation  of  the  transcription
factors NF-k B and AP-1 (Fig. 6). No activation of both
transcription  factors  at  this early  time-point  is  seen
with MTP-PE. Activation of NF-k B and AP-1 by MTP-PE
becomes detectable only after a lag phase of about
5 h, and is weaker pronounced than with LPS.
Effect of inhibitors of ERK-1, -2 and NF-k B on
the release of TNF-a , nitric oxide and PGE2
Inhibition of the map kinase isoenzymes ERK-1 and
ERK-2 by PD 9805929 leads to a decreased release of
TNF-a , nitric oxide and PGE2 (Table 1). TNF-a release
after LPS and MTP-PE, and PGE2 release after MTP-PE is
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Table 1. Effect of PD 98059 and BAY 11–7082 on the release of
TNF-a , nitric oxide and PGE2
a
Treatment TNF-a Nitric oxide
(% of control cells)
PGE2
LPS 100 100 100
+PD 98059 2 ± 4 28 ± 9 37 ± 7
+BAY 11–7082 1 ± 2 4 ± 5 40 ± 11
MTP-PE 100 100 100
+PD 98059 1 ± 2 69 ± 12 1 ± 2
+BAY 11–7082 111 ± 2 128 ± 29 159 ± 38
aMacrophages (48h) are incubated in RPMI medium containing 10%
newborn calf serum in the absence or presence of PD 90859 (10 m M,
4h) or BAY 11–7082 (10 m M, 1h). Thereafter, LPS (500ng/ml) or MTP-
PE (25mg/ml) is added. TNF-a is measured 4h after LPS and 24h after
MTP-PE; NO2
– and PGE2 are measured 24h after LPS and MTP-PE in
cell media as described in Materials and Methods. Values represent
means±SD of four to seven experiments.
FIG. 4. Western  blot analysis of  iNOS  and COX-2.  Macro-
phages  are  incubated  in  RPMI  medium  containing  10%
newborn calf serum without (C), with LPS (500ng/ml) or with
MTP-PE  (25 m g/ml).  At  indicated  time  points,  protein  is
isolated and Western blot analysis is performed as described
in  Materials and Methods. A  representative set  of  experi-
ments is shown, which is reproduced at least three times.
FIG.  5.  Effect  of  LPS,  MTP-PE  and  PGE2 on  map  kinase
isoenzymes ERK-1 and ERK-2. Macrophages are incubated in
Hanks’ solution without or with PGE2 (1 m M) as indicated.
After  10min,  vehicle  (C),  LPS  (500ng/ml)  or  MTP-PE
(25 m g/ml) is added for another 10min. Thereafter, cells are
lysed, subjected to SDS–PAGE, and an ‘in gel kinase assay’ is
performed  as  described  in  Materials  and  Methods.  The
position of the map kinase isoenzymes ERK-1 and ERK-2 is
indicated.  A  representative  set  of  experiments  is  shown,
which  is  reproduced  at  least  three  times.  PGE2 alone  is
without any effect.completely inhibited by PD 98059. The release of nitric
oxide after LPS and MTP-PE, and of PGE2 after MTP-PE,
is inhibited by PD 98059 by about 70%, 30% and 60%,
respectively (Table 1). Inhibition of the transcription
factor NF-k B by BAY 11–708230 has no effect on the
MTP-PE-induced  release  of TNF-a ,  nitric  oxide  and
PGE2 (Table 1). However, the LPS-induced release of
TNF-a and nitric oxide is completely inhibited by BAY
11–7082. The release of PGE2 after LPS is inhibited by
BAY 11–7082 by about 60% (Table 1).
Effect of PGE2 and PGD2
PGE2,  exogenously  added  to  macrophages,  inhibits
TNF-a release by LPS but not by MTP-PE (Table 2). In
contrast, the release of nitric oxide after LPS and MTP-
PE is enhanced by prior addition of PGE2. PGD2 is
without any effect (Table 2). In order to investigate at
which  level  PGE2 exerts  its  action,  the  effect  of
exogenously  added  PGE2 on  the  activation  of  map
kinase  isoenzymes  ERK-1  and  ERK-2 is determined.
PGE2 has no effect on the MTP-PE-induced activation
of  ERK-1  and  ERK-2  (Fig.  6). However, map  kinase
activation by LPS is completely suppressed.
Effect of LPS and MTP-PE on the cytotoxicity of
macrophages
MTP-PE  but not LPS activates macrophages to cyto-
toxicity  against  P815  tumor  target  cells  (Fig.  7).
Addition  of  neutralizing  antibodies  against  TNF-a
reduced the cytotoxic effect of MTP-PE by about 75%,
indicating  that  TNF-a is  involved  in  the  cytotoxic
reaction.
Discussion
Here we show that LPS and MTP-PE induce a release
of TNF-a ,  nitric  oxide,  PGE2 and  PGD2 in  macro-
phages. Both agents increase mRNA’s encoding TNF-a ,
iNOS  and  COX-2  indicating  their  action  at  the
transcriptional  level. We demonstrated recently that
macrophages  do  not  express  constitutive  NOS,31
which  suggests  that  the  observed  release  of  nitric
oxide after LPS and MTP-PE is catalysed by iNOS. The
formation of prostanoids after LPS is probably due to
the enhanced expression of COX-2 (Fig. 3C) and an
enhanced expression of cytosolic phospholipase A2.31
Since MTP-PE has no effect on cytosolic phospholi-
pase A2,31 prostanoid release after MTP-PE seems to
be triggered only by the enhanced expression of COX-
2. We could also demonstrate recently that LPS and
P. Dieter et al.
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FIG.  6.  Activation  of  NF-k B  and  AP-1.  Macrophages  are
incubated in Hanks’ solution without (C), with LPS (500ng/
ml),  or  with  MTP-PE  (25 m g/ml)  for  the  indicated  times.
Thereafter, cells are extracted and DNA binding activity to
NF-k B and AP-1 is monitored in electrophoretic mobility shift
assays as described in Materials and Methods. A representa-
tive set  of  experiments is  shown, which is  reproduced at
least three times.
FIG. 7. Effect of LPS and MTP-PE on cytotoxicity of macro-
phages against P815 tumor target cells. Macrophages (48h
in primary culture) are incubated for 6h  in RPMI medium
containing 10% newborn calf serum without (C), with LPS
(500ng/ml)  or  with  MTP-PE  (25 m g/ml).  Thereafter,  P815
target cells, and TNF-a neutralizing antibodies (Ab, 10 m l), as
indicated, are added. 48h later, cytolysis is determined as
described in Materials and Methods. Values represent means
± SD of five experiments.
Table  2.  Effect  of  PGE2 and  PGD2 on  LPS-  and  MTP-PE-
induced accumulation of TNF-a activity and NO2
– a
Treatment TNF-a activity
(Units ´ 10
–2/10
6 cells)
Nitric oxide
(NO2
–,nmol/10
6 cells)
None n.d. n.d.
LPS 20 ± 8 28 ± 11
+PGE2 1 ± 3 86 ± 9
+PGD2 22 ± 6 31 ± 7
MTP-PE 8 ± 3 26 ± 7
+PGE2 10 ± 5 79 ± 10
+PGD2 7 ± 4 24 ± 11
aMacrophages (48h) are incubated in RPMI medium containing 10%
newborn calf serum without (None), with PGE2 (1 m M) or with PGD2
(1 m M). 15min later, LPS (500ng/ml) or MTP-PE (25 m g/ml) is added.
TNF-a is  measured  4h  after  LPS  and  24h  after  MTP-PE;  NO2
– is
measured 24h after LPS and MTP-PE in cell media as described in
Materials and Methods. n.d., not detectable. Values represent means
± SD of four experiments.MTP-PE have no effect on COX-1 levels, and that the
constitutive nitric oxide synthase and secretory phos-
holipase A2s are not expressed in these cells.31
While the release of nitric oxide and PGD2 is almost
identical for both immunomodulators, the formation
of TNF-a and PGE2 after LPS and MTP-PE is different.
(1) Accumulation of TNF-a mRNA and TNF-a activity
after LPS is transient, a sustained release of TNF-a is
induced by MTP-PE. The finding, that  PGE2 inhibits
TNF-a release after LPS, but not after MTP-PE (Table
2), indicates that the mechanisms underlying TNF-a
formation are different for both immunomodulators.
It has been shown recently that the inhibition of the
LPS-induced TNF-a release by PGE2 can be mimicked
by cAMP,4 suggesting that intracellular cAMP mediates
the effect of PGE2. (2) PGE2 release after LPS is higher
than after MTP-PE. It has been suggested recently that
the high PGE2 formation after LPS might be due to an
activation of the PGE2 synthase.32,33
We demonstrated recently that both immunomodu-
lators do not induce an activation of the ‘phosphatidyl
inositol cycle’, of protein  kinase C isoenzymes or a
change of the intracellular calcium concentration.21
Here, we show that LPS and MTP-PE induce a rapid
activation of the map kinase isoenzymes ERK-1 and
ERK-2.  Inhibition  of  map  kinase  by  PD  98059
completely  suppresses TNF-a release  after  LPS  and
MTP-PE,  and  PGE2 release  after MTP-PE.  Release  of
nitric oxide and PGE2 after LPS are partially inhibited
by PD 98059. These data  indicate that activation  of
the  map  kinase  isoenzymes  ERK-1  and  ERK-2  is an
essential step for TNF-a release by LPS and MTP-PE,
and  for  PGE2 formation  by  MTP-PE.  Nitric  oxide
release, and PGE2 formation by LPS seem only to be
partially  mediated  by  map  kinase.  In  addition,  we
demonstrate here, that the transcription factors NF-k B
and  AP-1  are  activated  by  LPS.  Activation  of  both
transcription factors by LPS is observed already after
30 min,  and  persists  for  more  than  24 h.27 The
activation  of  NF-k B  and  AP-1  by  MTP-PE  is  much
weaker  pronounced,  and  becomes  detectable  only
after  5h.  Since  mRNAs  encoding TNF-a ,  iNOS  and
COX-2 are expressed at much earlier time-points, it is
very  unlikely  that  NF-k B  and AP-1  are  involved  in
these actions of MTP-PE. This conclusion is supported
by the finding that BAY 11–7072, an inhibitor for NF-
k B, has no effect on MTP-PE-induced responses. BAY
11–7072 completely suppresses the release of TNF-a
and nitric oxide by LPS, and inhibits PGE2 release by
LPS  by 60%, indicating  an  involvement  of NF-k B in
these actions of LPS.
The LPS-  but  not the  MTP-PE-induced relesase  of
TNF-a is specifically inhibited by PGE2. In contrast,
nitric oxide release by LPS and MTP-PE is enhanced
by PGE2.  PGE2 has  been shown  earlier to exert  its
suppressing  effect  on TNF-a release  by  LPS  at  the
transcriptional level.4 However, PGE2 does not affect
the  activation  of  NF-k B  or AP-1  by  LPS.27 Here  we
show, that PGE2 inhibits map kinase activation by LPS,
but  not  by  MTP-PE. This  indicates  that  the  mecha-
nisms of LPS and MTP-PE leading to activation of map
kinase are different.
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FIG. 8. Tentative scheme for the actions of LPS (A), MTP-PE (B) and PGE2 in macrophages.MTP-PE,  but  not  LPS,  induces  a  cytotoxicity  of
macrophages against tumor target cells. The MTP-PE
induced cytotoxicity is reduced by TNF-a neutralizing
antibodies,  indicating  that TNF-a is  involved  in  the
cytotoxic  action. The  lack  of  cytotoxicity  after  LPS
might  be  due  to  the  transient  release  of TNF-a ,  in
contrast to the sustained accumulation of TNF-a after
MTP-PE. These findings are in line with the fact, that
MTP-PE, when administered i.v., induces an antitumor
reactivity in animal models.16–20 Recently, it has been
proposed  that  the  cytotoxicity  of  macrophages
against the adenomacarcinoma line MCA26  is medi-
ated by TNF-a , and not by nitric  oxide.34 Our  data
support these findings, since LPS and MTP-PE induce
an identical release of nitric oxide, but differ in their
cytotoxic potencies.
Based on the results presented here, we propose
the following scheme for the regulatory role of PGE2
in  the  action  mechanisms  of  LPS  and  MTP-PE  in
macrophages (Fig. 8). LPS (Fig. 8A) activates rapidly
the map kinase isoenzymes ERK-1 and ERK-2 and the
transcription factors NF-k B and AP-1, which results in
a  synthesis  and  release  of  nitric  oxide, TNF-a and
PGE2. PGE2 reduces in a negative feedback loop the
activation of ERK-1 and ERK-2, nitric oxide release is
enhanced, TNF-a formation  is  suppressed,  cytotox-
icity  against  tumor  target  cells  is  low.  MTP-PE
activates rapidly  map kinase  isoenzymes  ERK-1  and
ERK-2, but not the transcription factors NF-k B and AP-
1. Activation  of  yet  unknown  transcription  factors
results in a synthesis and release of nitric oxide, TNF-a
and PGE2. PGE2 has no inhibitory effect on the map
kinase isoenzymes ERK-1 and ERK-2, TNF-a release is
not  suppressed, and  the macrophages  show a high
cytotoxicity against tumor target cells. Further experi-
ments have to be carried out to elucidate in detail the
molecular mechanisms of the regulatory function of
PGE2. These experiments include the investigation of
other  kinases  and  other  transcription  factors,35 –38,
which have been demonstrated in other cells to be
involved in the action of LPS, and in the formation of
TNF-a , nitric oxide and eicosanoids.
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